BioInvent International AB (publ) focuses on the research and development of immunomodulating antibodies for the treatment of cancer in Sweden, Europe, and internationally.
Exceptional growth potential with excellent balance sheet.
Share Price & News
How has BioInvent International's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BIX's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: BIX underperformed the German Biotechs industry which returned 6.2% over the past year.
Return vs Market: BIX underperformed the German Market which returned 15% over the past year.
Price Volatility Vs. Market
How volatile is BioInvent International's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is BioInvent International undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: BIX (€0.1) is trading below our estimate of fair value (€0.5)
Significantly Below Fair Value: BIX is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: BIX is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: BIX is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BIX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BIX is overvalued based on its PB Ratio (3.6x) compared to the DE Biotechs industry average (3.5x).
How is BioInvent International forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BIX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.4%).
Earnings vs Market: BIX is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: BIX's is expected to become profitable in the next 3 years.
Revenue vs Market: BIX's revenue (36% per year) is forecast to grow faster than the German market (5% per year).
High Growth Revenue: BIX's revenue (36% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BIX's Return on Equity is forecast to be very high in 3 years time (65.9%).
How has BioInvent International performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BIX is currently unprofitable.
Growing Profit Margin: BIX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BIX is unprofitable, and losses have increased over the past 5 years at a rate of -18.7% per year.
Accelerating Growth: Unable to compare BIX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BIX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).
Return on Equity
High ROE: BIX has a negative Return on Equity (-61.95%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
How is BioInvent International's financial position?
Financial Position Analysis
Short Term Liabilities: BIX's short term assets (SEK239.2M) exceed its short term liabilities (SEK52.4M).
Long Term Liabilities: BIX's short term assets (SEK239.2M) exceed its long term liabilities (SEK10.9M).
Debt to Equity History and Analysis
Debt Level: BIX is debt free.
Reducing Debt: BIX has not had any debt for past 5 years.
Inventory Level: BIX has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if BIX's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BIX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if BIX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is BioInvent International's current dividend yield, its reliability and sustainability?
Forecast Dividend Yield
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate BIX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate BIX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BIX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BIX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BIX's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Martin Welschof (58yo)
Dr. Martin Welschof, Ph.D has been the Chief Executive Officer of Opsona Therapeutics Limited since February 2012. Dr. Welschof has been Chief Executive Officer at BioInvent Intl AB (publ) since 2018. He i ...
|President & CEO||2.1yrs||no data||no data|
|Chief Financial Officer||4.1yrs||no data||0.023% SEK16.4k|
|Chief Scientific Officer||0yrs||no data||0.096% SEK69.3k|
|Senior Vice President of Technical Operations||3.4yrs||no data||0.098% SEK70.5k|
|Chief Medical Officer||3.1yrs||no data||no data|
Experienced Management: BIX's management team is considered experienced (3.3 years average tenure).
|Director||2.1yrs||no data||no data|
|Chairman of the Board||2.1yrs||kr180.00k||0.048% SEK34.4k|
|Independent Director||3.8yrs||kr129.00k||no data|
|Member of Scientific Advisory Board||3.1yrs||no data||no data|
|Independent Director||3.1yrs||kr169.00k||0.061% SEK43.8k|
|Employee Representative Director||6.3yrs||no data||0.0042% SEK3.0k|
|Independent Director||3.8yrs||kr129.00k||0.032% SEK23.3k|
|Employee Representative Director||3.1yrs||no data||0.0030% SEK2.2k|
|Chairman of the Scientific Advisory Board||3.1yrs||no data||no data|
|Member of Scientific Advisory Board||3.1yrs||no data||no data|
Experienced Board: BIX's board of directors are considered experienced (3.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 28.9%.
BioInvent International AB (publ)'s company bio, employee growth, exchange listings and data sources
- Name: BioInvent International AB (publ)
- Ticker: BIX
- Exchange: DB
- Founded: 1997
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: kr757.673m
- Listing Market Cap: kr71.937m
- Shares outstanding: 501.77m
- Website: https://www.bioinvent.com
Number of Employees
- BioInvent International AB (publ)
- The Gamma Building
- Sölvegatan 41
- 223 70
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|BINV||OM (OMX Nordic Exchange Stockholm)||Yes||Ordinary Shares||SE||SEK||Jun 2001|
|BIX||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Jun 2001|
|0H22||LSE (London Stock Exchange)||Yes||Ordinary Shares||GB||SEK||Jun 2001|
|BOVN.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||Jun 2001|
|BINVS||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Ordinary Shares||GB||SEK||Jun 2001|
BioInvent International AB (publ) focuses on the research and development of immunomodulating antibodies for the treatment of cancer in Sweden, Europe, and internationally. The company’s lead drug candidate is BI-1206, a monoclonal antibody targeting CD32b, which is in Phase I/II clinical trials in patients with B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia who are resistant to rituximab. It has a collaboration agreement with Oncurious to develop TB-403, an antibody that targets the protein PlGF, which is in Phase I/II clinical trials used for the treatment of patients with medulloblastoma; and with Oxurion to develop THR-317 that is in Phase I/II clinical trials used for the treatment of patients with diabetic macular edema. The company is also developing immuno-modulatory antibodies, such as cancer-associated regulatory T cells and tumour-associated myeloid-derived suppressor cells, as well as BI-1808, an antibody candidate. It has a strategic collaboration with Pfizer Inc. for the development of antibodies against tumour-associated myeloid cells; and partnership and collaboration with Transgene to co-develop multi-functional oncolytic viruses encoding for undisclosed antibodies sequences for treating a range of solid tumors. The Company was founded in 1997 and is based in Lund, Sweden.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/16 21:09|
|End of Day Share Price||2020/02/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.